Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRA | P16234 | 14/20 | 0.58 |
| ▸ | FLT3 | P36888 | 10/20 | 0.58 |
| ▸ | CDK2 | P24941 | 8/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727080 | 1.00 | PDGFRA (0.58) | PDGFRAFLT3CDK2SRCCCNE1 | |
| SCHEMBL1591420 | 0.90 | FLT3 (0.56) | PDGFRAFLT3CDK2SRCCCNE1 | |
| SCHEMBL23468403 | 0.89 | FLT3 (0.55) | PDGFRAFLT3CDK2SRCCCNE1 | |
| SCHEMBL4565801 | 0.87 | CDK2 (0.48) | PDGFRAFLT3CDK2SRCCCNE1 | |
| SCHEMBL3585775 | 0.84 | CDK1 (0.54) | PDGFRAFLT3CDK2SRCCCNE1 | |
| SCHEMBL1590863 | 0.81 | NPC1 (0.50) | CDK2 | |
| SCHEMBL13444871 | 0.81 | FLT3 (0.73) | PDGFRAFLT3CDK2SRCCCNE1 | |
| SCHEMBL1590688 | 0.80 | FLT3 (0.52) | PDGFRAFLT3CDK2SRCCCNE1 | |
| SCHEMBL1590850 | 0.79 | HPGD (0.46) | CDK2SRCCCNE1 | |
| SCHEMBL14097812 | 0.78 | PDGFRA (0.42) | PDGFRAFLT3CDK2SRCCCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2010-03-04 | — | — | US | disclosed |
| EP-2124954-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008094737-A2 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | IRM LLC (BM) | 2008-08-07 | — | — | WO | disclosed |
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | IRM LLC (BM) | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124637-A1 | Compounds and compositions as inhibitors of receptor tyrosine kinase activity | BMX, LCK, FYN | PDGFRA 35/4885FLT3 5/4885CDK2 444/4885 |
| US-20100056494-A1 | PURINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS FOR THE TREATMENT OF PLASMODIUM RELATED DISEASES | ADK, PNP, DCK | PDGFRA 1321/4885FLT3 317/4885CDK2 276/4885 |
| US-20110092491-A1 | Compounds and Compositions as Inhibitors of Receptor Tyrosine Kinase Activity | BMX, LCK, FYN | PDGFRA 35/4885FLT3 5/4885CDK2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.